Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids
The purpose of this study is to determine the efficacy and safety of TAK-385, once daily (QD), for 12 weeks in women with uterine fibroids.
Uterine Fibroids
DRUG: TAK-385|DRUG: TAK-385|DRUG: TAK-385|DRUG: Placebo
Decrease in menstrual blood loss, Blood loss will be assessed using the Pictorial Blood Loss Assessment Chart (PBAC)., Week 12 (one menstrual cycle)
Decrease in menstrual blood loss, Blood loss will be assessed using PBAC, Up to Week 6|Decrease in menstrual blood loss, Blood loss will be assessed using PBAC, Up to Week 12.|Amenorrhea, Amenorrhea will be assessed using PBAC, Week 12 (one menstrual cycle).|Amenorrhea, Amenorrhea will be assessed using PBAC, Up to Week 6.|Amenorrhea, Amenorrhea will be assessed using PBAC, Up to Week 12.|Change in menstrual blood loss, Change in menstrual blood loss measured by PBAC, Week 12 (one menstrual cycle)|Myoma Volume, Up to Week 12.|Uterine Volume, Up to Week 12.|Hemoglobin Concentration in Blood, Up to Week 12.|Pain Symptom, Measured by Numerical Rating Scale., Up to Week 12.|Other Clinical Symptoms, Assessed by clinical laboratory tests, Up to Week 12.|Quality of Life (QOL) Score, QOL will be assessed using Uterine Fibroid Symptom and Quality of Life (UFS-QOL), Up to Week 12.|Bone Mineral Density, Measured by Dual-energy X-ray absorptiometry (DXA), Up to Week 12.|Treatment-emergent Adverse Events, Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through the last visit (Week 16), Up to Week 16.|Vital Signs, Vital signs will include body temperature, sitting blood pressure, and pulse (bpm)., Up to Week 12.|Body Weight, Up to Week 12.|Electrocardiograms, Up to Week 12.|Laboratory Values, Up to Week 12|Serum NTx, NTx is one of the biochemical bone metabolism markers, Up to Week 12|Serum BAP, BAP is one of the biochemical bone metabolism markers, Up to Week 12
This study is a Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled for evaluation of the efficacy and safety of TAK-385 10, 20, and 40 mg (p.o.) following once daily administration for 12 weeks in women with uterine fibroids.